Compare GeneDx Holdings Corp (WGS) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Walmart Stores Inc — how do they compare? GeneDx Holdings Corp trades at $67.33 (market cap $2.02B), while Walmart Stores Inc trades at $111.35 (market cap $877.15B). The key difference: Walmart Stores Inc is far larger — about 434.2× GeneDx Holdings Corp's market cap, and Walmart Stores Inc pays a 0.9% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Walmart Stores Inc for 101 Days on average.
| WGS | WMT | |
|---|---|---|
Market Cap | $2.02B | $877.15B |
Volume | 734,640 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $167.51 | $134.20 |
52-Week Low | $34.51 | $100.61 |
Typical Hold Time | 19 Days | 101 Days |
Enterprise Value | $2.05B | $939.38B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Walmart (WMT) trades at $110.56, up 2.27% with a bullish technical signal. The company demonstrates strong fundamentals with revenue reaching $680.99B in 2025 and consistent earnings beats. Recent news highlights expansion in AI capabilities, Marketplace growth exceeding 50%, and new Medicare Advantage partnerships. The stock trades at a P/E of 40.06 and P/S of 1.2, reflecting premium valuation amid solid operational performance.
Walmart presents a compelling growth story with expanding digital services and market share gains. The primary investment opportunity lies in continued e-commerce momentum and operational efficiency. Key risks include valuation sensitivity, rising costs, and consumer spending pressures. Analyst consensus remains strongly bullish with a $128.84 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
